HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. HARVONI is used with ribavirin in GT 1 patients with decompensated cirrhosis and in GT 1 or 4 liver
transplant recipients without cirrhosis or with compensated cirrhosis.

CHOOSE SOFOSBUVIR-BASED REGIMENS

Over 900,000
patients with HCV

have been treated with
sofosbuvir-based regimens.1,a

aSource: IMS Data from December
2013 through September 2019.

SUPPORT PATH IS HERE TO HELP

Patient support program for HARVONI® (ledipasvir/sofosbuvir) Support Path

Support Path can help patients understand insurance coverage and financial support options to get started on treatment.

Visit mysupportpath.com or call to connect live with a Support Path Program Navigator at 1-855-7-MYPATH (1-855-769-7284).

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Contraindications

Warnings and Precautions

Adverse Reactions

Drug Interactions

Consult the full Prescribing Information for HARVONI for more information on potentially significant drug interactions, including clinical comments.

Please see full Prescribing Information for HARVONI, including BOXED WARNING.

1. Data on file. Gilead Report on IMS National Prescription Audit December 2013 through September 2019.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences, as regulatory control, legal requirements, and/or medical practices may vary in other countries.

Gilead corporate logo

HARVONI, the HARVONI logo, SUPPORT PATH, the SUPPORT PATH logo, GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF HEPATITIS
B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS: Test all patients for

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HARVONI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment